Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (762)	12/24/2002 8:55:05 AM
From: Joseph B. Schmidt	Read Replies (1) \| Respond to of 23958

One to consider for an addition is WIKS, latest 10Q shows a $3.00+ book value and I've been a buyer: biz.yahoo.com

To: Sergio H who wrote (762)	12/24/2002 9:58:06 AM
From: JoeinIowa	Read Replies (1) \| Respond to of 23958

Sergio, Add ALT to the Folio($1.90) as it has a pretty interesting story coming up. I know there are a number of guys here who like a good story. They are presenting at a conference in early January and they expect results from their phase II studies in the next 3 months. If you have not seen them before you may be pretty interested in what their drugs claim to do. LOL. Don't want to ruin the story for you. Joe

To: Sergio H who wrote (762)	12/24/2002 11:59:04 PM
From: JoeinIowa	Respond to of 23958

Sergio, Well the kids are finally in bed. My wife is wrapping the last gifts(it would be a dead give away that Santa does not exist if I wrapped gifts - those corners are impossible to get straight.) Of course A Christmas Carol is on. That leaves me a few moments to catch up on my e-mail and reading. Here are a few of the items I like about VASO. 1)Company was just approved on 12/11 in EU. This enables the Company to begin marketing new or improved EECP products in all 15 EU countries and cooperating partner countries without undergoing separate review and inspection for each product. As a result, Vasomedical has begun marketing its Model TS3 EECP system, which includes the Company's patent-pending congestive heart failure treatment and oxygen saturation monitoring technologies, throughout the EU. 2)Hired a new CEO and a new President with lots of experience. Mr. Paulson has a proven business track record with over 40 years experience in the healthcare industry, having held senior management positions at leading medical devices companies as well as in the healthcare investment banking field. Mr. Paulson began his career at Becton Dickinson, a NYSE-traded company engaged in the manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products, where he served for over 25 years in various capacities, and was ultimately appointed as executive vice president and chief operating officer. Mr. Cash brings nearly 25 years of experience in the medical device industry to his position at Vasomedical. He most recently served as Corporate Vice President of Datascope Corporation and President of its wholly-owned subsidiary, Intervascular, Inc., where he led this global unit in achieving increased profitability and revenue growth, and organized the launch of a direct sales and marketing effort in the US market. 3)Continued articles on the benefits of EECP. One study showed it was as effective as By-pass surgery one year later. This non-invasive procedure works and from many of the articles I have read can make a huge difference in the quality of life for people who get the treatment. 4) Recently pre-released 2nd quarter results. Sales grew 50% from last quarter and losses seem to be minimal. Expect sales to continue to grow and more positive news going forward. Not far from break-even at these sales levels. Well thats all I have for now. I hope everyone has a great Christmas. HOHOHO. Joe